News | CGA-IGC

Supporting Family Caregivers: November Is National Family Caregivers Month!

Michelle Springer, MS, CGC - Chair , CGA-IGC Communications Committee November is National Family Caregivers Month , a time to honor the millions of Americans who play an indispensable role in attending to the needs of their loved ones. Family caregivers are often the unsung heroes of healthcare, serving as a bridge between their loved one and providers. They help navigate complex medical systems, attend appointments, manage complex medical routines, and provide emotional su

Awareness

CGA-IGC

4 hours ago1 min read

Joint Webinar with ACG: Chemoprevention in hereditary cancer syndromes – FAP and Lynch Syndrome

If you missed our fifth webinar of the year, or would like to revisit the discussion, the full session is now available on-demand for CGA-IGC members. Not yet a member? You can join here . In collaboration with the American College of Gastroenterology, this webinar featured Katharine Germansky, MD from Beth Israel Deaconess Medical Center, and Pooja Dharwadkar, MD from University of California, San Francisco, who delivered an in-depth look at chemoprevention in hereditary

CGA-IGC

6 days ago2 min read

National Family History Month: A Reminder for Providers and Genetic Counselors!

October’s National Family History Month is an important opportunity to emphasize how family history drives cancer risk assessment, genetic referrals, and prevention. Even with growing access to genetic testing, a detailed family history often remains the first and most actionable clue to hereditary cancer risk. Providers and genetic counselors are uniquely positioned to help patients understand why family health information matters and encourage them to share it with relat

CGA-IGC

Oct 222 min read

Baby Aspirin and Cancer Prevention in Lynch Syndrome: New CaPP3 Results

Professor Sir John Burn joined Dr. Swati Patel at the CGA-IGC 2025 Annual Meeting to share long-awaited results from the CaPP3 trial, a follow-up to the landmark CAPP2 study that first demonstrated aspirin’s ability to reduce cancer risk in people with Lynch syndrome. While some questions remain unanswered and more research is needed, Sir John Burn discusses the results from the study and the considerations surrounding aspirin as a chemopreventive in Lynch syndrome.

CGA-IGC

Oct 131 min read